Kaitlyn D’Onofrio

DocwireNews

A newly published study identified <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/understanding-hr-positive-breast-cancer-and-its-treatment/">TRPV6</a> as a potentially effective therapy in multiple <a href="https://www.docwirenews.com/docwire-pick/cardiology-picks/cancer-patients-high-risk-heart-disease-stroke/">cancers</a>.&ldquo;Two decades ago a class of ion channels, hitherto unsuspected, was discovered. In mammals these Transient Receptor Potential channels (TRPs) have not only expanded in number (to 26 functional channels) but also expanded the view of our interface with the physical and chemical environment,&rdquo; explained the study authors, whose work was published in the <a href="https://www.jcancer.org/v11p0374.htm">Journal of Cancer</a>. The researchers added, &ldquo;Many TRP channels are major players in nociception and integration of pain signals. One member of the vanilloid sub-family of channels is TRPV6. This channel is highly selective for divalent cations, particularly calcium, and plays a part in general whole-body calcium homeostasis, capturing calcium in the gut from the diet. TRPV6 can be greatly elevated in a number of cancers deriving from epithelia and considerable study has been made of its role in the cancer phenotype where calcium control is dysfunctional.&rdquo;SOR-C13 is a selective TRPV6 inhibitor and is the first to undergo clinical trial observation and is currently being assessed at MD Anderson Cancer Center. According to a press release, &ldquo;SOR-C13 binds with high affinity and selectivity and disrupts the function of TRPV6. TRPV6 plays a central role in a biochemical cascade that results in the upregulation of an array of pro-cancerous genes and is considered to be an important target for novel anticancer therapy.&rdquo;In a summary of their research findings, the study authors wrote that previous research observed good outcomes for TRPV6 inhibition in animal models, and more recent findings suggest its efficacy in humans, too. Looking ahead, they said, &ldquo;The key issues to be resolved for a successful antagonist of TRPV6 are: an IC50 low enough to be clinically meaningful (i.e., required dose), specificity in inhibiting only TRPV6, low human toxicity, bio-stability, and cost. Still, it is unclear how the expression of TRPV6 gene and production of protein is up regulated in these cancers and that may offer another route to exploit TRPV6.&rdquo;SOR-C13 was developed by Soricimed.&ldquo;TRPV6 has been discussed in the literature as a target for cancer therapy for nearly 20 years,&rdquo; said corresponding study author professor Jack Stewart, co-founder and chief scientific officer of Soricimed, <a href="https://finance.yahoo.com/news/soricimed-announces-journal-cancer-publication-130000217.html">in a press release</a>. &ldquo;This article compiles everything we know about TRPV6 &ndash; how it works, its mechanism of action as an oncochannel and what controls its gene expression. In addition to demonstrating TRPV6 as a useful target for solid cancers, this publication outlines how we can exploit TRPV6&rsquo;s overexpression to treat several cancer types.&rdquo;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

TRPV6 Appears Promising in Multiple Cancers

Oncology

A newly published study identified TRPV6 as a potentially effective therapy in multiple cancers. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe